• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Clene Inc.

    6/5/26 4:09:36 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    S-8 1 clnn20260514_s8.htm FORM S-8 clnn20260514_s8.htm

     

    As filed with the Securities and Exchange Commission on June 5, 2026

    Registration No. 333-



    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549


    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    CLENE INC.

    (Exact name of registrant as specified in its charter)


     

    Delaware

     

    85-2828339

    (State or other jurisdiction

     

    (I.R.S. Employer

    of incorporation or organization)

     

    Identification No.)

         

    6550 South Millrock Drive, Suite G50

    Salt Lake City, Utah

     

    84121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     


    Clene Inc. Amended 2020 Stock Plan

    (Full title of the plan)


    Robert Etherington

    President and Chief Executive Officer

    6550 South Millrock Drive, Suite G50

    Salt Lake City, Utah 84121

    (Name and address of agent for service)

    (801) 676-9695

    (Telephone number, including area code, of agent for service)


    Copies to:

    Jerry Miraglia, Esq.

     

    David Marx, Esq.

    General Counsel and Corporate Secretary   Joshua Erekson, Esq.

    500 Principio Parkway West, Suite 400

     

    Dorsey & Whitney LLP

    North East, Maryland 21901

     

    111 S. Main Street, Suite 2100

    Tel: (443) 273-1645   Salt Lake City, Utah 84111

     

     

    Tel: (801) 933-7360

     


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is filed by Clene Inc. (the “Company”), pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, to register 1,000,000 additional shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), under the Clene Inc. Amended 2020 Stock Plan (the “2020 Stock Plan”). The amendment to increase the number of shares of Common Stock reserved for issuance under the 2020 Stock Plan from 3,220,000 to 4,220,000 was approved by the Board of Directors of the Company on April 3, 2026, and by the stockholders of the Company on May 21, 2026. This Registration Statement hereby incorporates by reference the contents of the Company’s registration statement on Form S-8 filed with the Securities and Exchange Commission on March 29, 2021 (Registration No. 333-254810), registration statement on Form S-8 filed with the Securities and Exchange Commission on June 16, 2023 (Registration No. 333-272744), registration statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2024 (Registration No. 333-279987), and registration statement on Form S-8 filed with the Securities and Exchange Commission on September 5, 2025 (Registration No. 333-290072), to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

     

     

     

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 8. Exhibits.

     

    Exhibit Number   Exhibit Description
    3.1   Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on May 11, 2023).
    3.2   Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on May 30, 2024).
    3.3   Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the registrant on July 9, 2024).
    3.4   Bylaws of Clene Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed by the Registrant on January 5, 2021).
    5.1*   Opinion of Dorsey & Whitney LLP.
    23.1*   Consent of Dorsey & Whitney LLP (included as part of Exhibit 5.1).
    23.2*   Consent of Deloitte & Touche LLP.
    24.1*   Power of Attorney (included on signature page of the Registration Statement).
    99.1   Clene Inc. Amended 2020 Stock Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant on May 22, 2026).
    107*   Filing Fee Table.

    *

    Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on June 5, 2026.

     

     

     

     

     

     

    CLENE INC.

     

     

     

     

     

     

    By:

    /s/ Robert Etherington

     

     

     

    Robert Etherington

     

     

     

    President and Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Robert Etherington attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this Registration Statement (and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act, (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Robert Etherington   President, Chief Executive Officer, and Director   June 5, 2026
    Robert Etherington   (Principal Executive Officer)    
             
    /s/ Morgan R. Brown   Chief Financial Officer   June 5, 2026
    Morgan R. Brown   (Principal Financial and Accounting Officer)    
             
    /s/ David J. Matlin   Chairman of the Board   June 5, 2026
    David J. Matlin        
             
    /s/ Arjun Desai   Director   June 5, 2026
    Arjun Desai        
             
    /s/ Jonathon T. Gay   Director   June 5, 2026
    Jonathon T. Gay        
             
    /s/ Matthew Kiernan   Director   June 5, 2026
    Matthew Kiernan        
             
    /s/ Shalom Jacobovitz   Director   June 5, 2026
    Shalom Jacobovitz        
             
    /s/ Vallerie V. McLaughlin   Director   June 5, 2026
    Vallerie V. McLaughlin        
             
    /s/ Alison H. Mosca   Director   June 5, 2026
    Alison H. Mosca        
             
    /s/ Reed Neil Wilcox   Director   June 5, 2026
    Reed Neil Wilcox        

     

     
    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:03:40 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Desai Arjun Jj

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:02:42 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mosca Alison

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:02:03 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

    After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturityIn May 2026, Clene completed a $7 million underwritten registered direct offering with a

    5/14/26 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go

    5/6/26 7:00:00 AM ET
    $ATCH
    $CLNN
    $CRGO
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces $7 Million Underwritten Offering of Common Stock

    SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor.   The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are

    5/5/26 8:45:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/2/24 12:58:21 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clene downgraded by Oppenheimer

    Oppenheimer downgraded Clene from Outperform to Perform

    10/4/22 8:58:30 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Clene with a new price target

    H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

    7/18/22 7:19:07 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Clene with a new price target

    Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

    5/2/22 9:11:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    SEC Filings

    View All

    SEC Form S-8 filed by Clene Inc.

    S-8 - Clene Inc. (0001822791) (Filer)

    6/5/26 4:09:36 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Clene Inc.

    SD - Clene Inc. (0001822791) (Filer)

    5/22/26 4:43:43 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    5/22/26 4:37:23 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Clene Appoints Neurology Expert to Executive Team

    SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

    3/16/23 9:46:10 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces New Chief Financial Officer Morgan Brown

    SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

    2/1/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

    SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

    8/5/21 4:01:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Clene Inc.

    SC 13D/A - Clene Inc. (0001822791) (Subject)

    10/2/24 4:38:44 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Financials

    Live finance-specific insights

    View All

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

    The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

    10/3/22 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

    SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

    9/30/22 4:12:25 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care